ADZYNMA
STN: 125795
Proper Name: ADAMTS13, recombinant-krhn
Tradename: ADZYNMA
Manufacturer: Takeda Pharmaceuticals U.S.A., Inc.
Indication:
- Prophylactic or on-demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP)
Product Information
- Package Insert and Patient Information - ADZYNMA
- Instructions for Use - ADZYNMA
- Demographic Subgroup Information – ADAMTS13, recombinant-krhn [ADZYNMA]
Refer to Section 1.1 of the Clinical Review Memo for information about participation in the clinical trials and any analysis of demographic subgroup outcomes that is notable.
Latest Safety Information
- FDA Investigating Death Due to Neutralizing Antibodies to ADAMTS13 following Adzynma Treatment of Congenital Thrombotic Thrombocytopenic Purpura
November 21, 2025